CX691 as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer’s disease

Document Type : Original Article


1 Physiology-Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

2 Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

3 School of Medicine and Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran


Objective(s): Growing evidence suggests that dysfunction of the glutamatergic system and α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptors are involved in pathology of Alzheimer’s disease (AD). Because AMPA receptors play a key role in plasticity synaptic regulation, positive modulation of these receptors may rescue the cognitive deficits in the AD. The aim of this study was to explore the effect of CX691, a specific positive allosteric modulator of the AMPA-type glutamate receptors (Ampakine), on spatial learning and memory in a rat model of AD.
Materials and Methods: For induction of AD, amyloid-beta 1-42 (Aβ1-42) was microinjected into the hippocampus of male Wistar rats (250-300 g). The Morris water maze (MWM) test was used to evaluate the effect of CX691 (0.03 and 0.3 mg/kg, twice a day for 10 days, orally) on spatial learning and memory of rats. In order to evaluate the protein expression of brain-derived neurotrophic factor (BDNF) in hippocampus tissue, ELISA test was used.
Results: The obtained data showed that treatment with CX691 (0.3 mg/kg) improves the impairment of spatial learning and memory in AD rats. Also, treatment with CX691 (0.3 mg/kg), increased the BDNF protein level in hippocampus tissue of AD rats compared to non-treated animals.
Conclusion: The CX691 can improve the BDNF protein expression as well as spatial performance of learning and memory in AD rats.


Main Subjects

1. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med. 2008;12:38–55.
2. Imtiaz B, Tolppanen A-M, Kivipelto M, Soininen H. Future directions in Alzheimer’s disease from risk factors to prevention. Biochem Pharmacol. 2014;88:661–670.
3. Guntupalli S, Widagdo J, Anggono V. Amyloid-β-induced dysregulation of AMPA receptor trafficking. Neural Plast. 2016; 2016: 3204519.
4. Reinders NR, Pao Y, Renner MC, Silva-Matos CM da, Lodder TR, Malinow R, et al. Amyloid-β effects on synapses and memory require AMPA receptor subunit GluA3. Proc Natl Acad Sci. 2016;113:E6526–E6534.
5. Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer’s disease. Philos Trans-R Soc Lond Ser B Biol Sci. 2003;358:821–828.
6. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci. 2002;25:103–126.
7. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm. 2014; 121:799–817.
8. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846–851.
9. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991;7:695–702.
10. Tanila H. The role of BDNF in Alzheimer’s disease. Neurobiol Dis. 2017;97:114–118.
11. Partin KM. AMPA receptor potentiators: from drug design to cognitive enhancement. Curr Opin Pharmacol. 2015;20:46–53.
12. Jardemark K, Marcus MM, Malmerfelt A, Shahid M, Svensson TH. Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl). 2012;221:115–131.
13. Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007;32:1272–1283.
14. Jourdi H, Hsu Y-T, Zhou M, Qin Q, Bi X, Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci. 2009;29:8688–8697.
15. Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci. 2009;106:4906–4911.
16. O’Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord. 2004;3:181–194.
17. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther. 1999;289:392–397.
18. Mozafari N, Moghadam-Ahmadi A, Shamsizadeh A, Fatemi I, Allahtavakoli M, Kaeidi A. The effect of ampakine Farampator (CX691) on working memory in a rat model of Alzheimer’s disease induced by Amyloid beta 1-42. Iran J Physiol Pharmacol. 2016;2:113–120.
19. Chang PK-Y, Verbich D, McKinney RA. AMPA receptors as drug targets in neurological disease–advantages, caveats, and future outlook. Eur J Neurosci. 2012;35:1908–1916.
20. Zhang J, Ke K-F, Liu Z, Qiu Y-H, Peng Y-P. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of aβ1-42-induced Alzheimer’s disease model rats. PloS One. 2013;8:e75786.
21. Zhang L, Fang Y, Lian Y, Chen Y, Wu T, Zheng Y, et al. Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer’s disease induced by aβ1-42. PloS One. 2015;10:e0122415.
22. Forner S, Baglietto-Vargas D, Martini AC, Trujillo-Estrada L, LaFerla FM. Synaptic impairment in Alzheimer’s disease: a dysregulated symphony. Trends Neurosci. 2017;40:347–357.
23. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831–843.
24. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron. 2003;37:925–937.
25. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866–2875.
26. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch G. A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 1994;638:343–346.
27.  Yamada KA. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol Dis. 1998;5:67–80.
28. Lynch G, Gall CM. Ampakines and the threefold path to cognitive enhancement. Trends Neurosci. 2006;29:554–562.
29. Stäubli U, Perez Y, Xu F, Rogers G, Ingvar M, Stone-Elander S, et al. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci. 1994;91:11158–11162.
30. Granger R, Staubli U, Davis M, Perez Y, Nilsson L, Rogers GA, et al. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse. 1993;15:326–329.
31. Larson J, Lieu T, Petchpradub V, LeDuc B, Ngo H, Rogers GA, et al. Facilitation of olfactory learning by a modulator of AMPA receptors. J Neurosci. 1995;15:8023–8030.
32. Shors TJ, Servatius RJ, Thompson RF, Rogers G, Lynch G. Enhanced glutamatergic neurotransmission facilitates classical conditioning in the freely moving rat. Neurosci Lett. 1995;186:153–156.
33. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci. 1998;18:2740–2747.
34. Lebrun C, Pillière E, Lestage P. Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. Eur J Pharmacol. 2000;401:205–212.
35. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2014;220:223–50.
36. Scharfman HE, MacLusky NJ. Differential regulation of BDNF, synaptic plasticity and sprouting in the hippocampal mossy fiber pathway of male and female rats. Neuropharmacology. 2014;76:696–708.
37. Christensen R, Marcussen AB, Wörtwein G, Knudsen GM, Aznar S. Aβ(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Exp Neurol. 2008;210:164–71.
38. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med. 2009;15:331–337.
39. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209–219.
40. Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013;33:15596–15602.
41. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Rev. 1998;27:1–39.
42. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol. 2001;63:71–124.
43. Lindvall O, Kokaia Z, Bengzon J, Elme E, Kokaia M, others. Neurotrophins and brain insults. Trends Neurosci. 1994;17:490–496.
44. Schinder AF, Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 2000;23:639–645.
45. Legutko B, Li X, Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology. 2001;40:1019–1027.
46. Lockhart BP, Rodriguez M, Mourlevat S, Peron P, Catesson S, Villain N, et al. S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures. Eur J Pharmacol. 2007;561:23–31.
47. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20:8–21.
48. Woolley ML, Waters KA, Gartlon JE, Lacroix LP, Jennings C, Shaughnessy F, et al. Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2, 1, 3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl). 2009;202:343–354.